Aaron Boster

Remyelination is when you would put it back on.

And I hypothesize that there's three kinds of therapies that we need to cure MS.

The first is a remyelinating agent, and we don't have one yet.

We've been working on it.

We have failed multiple times in trying to develop a remyelinating agent.

We've had some close ones where we were really excited and then fell on our noses.

Yeah.

So anti-lingo.

Yep.

And it didn't work out.

The second thing that we need is a neuroprotective agent.

And unfortunately, we really don't have that yet.

The third thing that we need and we have in spades is specific anti-inflammatories.

And I don't mean anti-inflammatory like an aspirin.

I mean central nervous system anti-inflammatories, like you mentioned, B-cell depleters like Ocrevus, Ocrelizumab.

So this is a huge area of interest in MS research and in specific in like MS therapeutics.

We're not really working so much anymore on like the next anti-inflammatory because we have those.

A lot of the efforts are instead being placed on some of these other areas, which is appropriate and really, really exciting.

This is a very important topic.

And so what you're talking about is a stem cell transplant.